Pt ID | Diagnosis | Disease history | Age at vedolizumab initiation (years) | Follow-up duration since vedolizumab initiation (months) | Previous adalimumab (yes/no) | Previous infliximab (yes/no) | Most recent anti-TNF | Duration of anti-TNF (months) | Type of loss of response to anti-TNF (primary or secondary) |
1 | UC | Pancolitis UC since late 2016 | 17 | 19 | No | Yes | Infliximab | 7 | Secondary |
2 | Crohn | Ileocolonic Crohn’s disease since April 2013 | 12 | 11 | Yes | Yes | Adalimumab | 17 | Secondary |
3 | UC | Pancolitis UC since early 2011 | 17 | 20 | Yes | Yes | Adalimumab | 10 | Secondary |
4 | UC | Pancolitis since March 2010 | 16 | 10 | Yes | Yes | Adalimumab | 4 | Secondary |
5 | UC | Pancolitis since October 2015 | 17 | 11 | No | Yes | Infliximab | 1 | Primary |
6 | UC | Pancolitis UC since 2014 | 18 | 7 | Yes | Yes | Infliximab | 8 | Secondary |
7 | Crohn | Ileocolonic Crohn’s disease since July 2015 | 11 | 16 | No | Yes | Infliximab | 6 | Secondary |
8 | UC | Pancolitis UC since January 2012 | 7 | 16 | No | Yes | Infliximab | 4 | Secondary |
9 | UC | Ileocolonic Crohn’s disease since June 2016 | 15 | 5 | No | Yes | Infliximab | 1 | Secondary |
10 | UC | Pancolitis UC since August 2006 | 21 | 9 | No | Yes | Infliximab | 10 | Secondary |
11 | UC | Pancolitis UC since September 2015 | 14 | 12 | No | Yes | Infliximab | 2 | Primary |
12 | UC | Pancolitis UC since July 2013 | 17 | 12 | No | Yes | Infliximab | 2 | Secondary |
UC, ulcerative colitis; TNF, tumour necrosis factor,